Cargando…
Recent Advances in Anticoagulant Treatment of Immune Thrombosis: A Focus on Direct Oral Anticoagulants in Heparin-Induced Thrombocytopenia and Anti-Phospholipid Syndrome
For more than 10 years, direct oral anticoagulants (DOACs) have been increasingly prescribed for the prevention and treatment of thrombotic events. However, their use in immunothrombotic disorders, namely heparin-induced thrombocytopenia (HIT) and antiphospholipid syndrome (APS), is still under inve...
Autores principales: | Carré, Julie, Jourdi, Georges, Gendron, Nicolas, Helley, Dominique, Gaussem, Pascale, Darnige, Luc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744910/ https://www.ncbi.nlm.nih.gov/pubmed/35008518 http://dx.doi.org/10.3390/ijms23010093 |
Ejemplares similares
-
Direct Oral Anticoagulants as Successful Treatment of Heparin-Induced Thrombocytopenia: A Parisian Retrospective Case Series
por: Carré, Julie, et al.
Publicado: (2021) -
Comparative effectiveness and safety of anticoagulants for the treatment of heparin‐induced thrombocytopenia
por: Nilius, Henning, et al.
Publicado: (2021) -
Thrombocytopenia Due to Direct Oral Anticoagulation and Low-Molecular-Weight Heparin
por: Tucker, Madeline, et al.
Publicado: (2021) -
Cost-effectiveness analysis of alternative anticoagulation in suspected heparin-induced thrombocytopenia
por: Tuleja, Aleksandra, et al.
Publicado: (2022) -
Anticoagulation during continuous renal replacement therapy with lepirudin in patients with heparin-induced thrombocytopenia
por: Schroeder, T, et al.
Publicado: (2005)